Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US STOCKS-Wall St flat after retail sales, Nasdaq edges higher

Mon, 13th May 2013 16:41

* Core U.S. retail sales rise 0.5 percent in April

* Yum Brands falls as monthly Chinese sales drop

* Crude oil falls, pressuring energy companies

* Indexes: Dow down 0.2 pct, S&P up 0.1 pct, Nasdaq up 0.3pct

By Ryan Vlastelica

NEW YORK, May 13 (Reuters) - U.S. stocks were mostly flat onMonday as investors paused following a rally that took indexesto record highs, though a strong read on retail sales limiteddeclines and the Nasdaq ticked up on a rally in Netflix.

The S&P 500 has jumped more than 14 percent so far thisyear, a rally that has repeatedly taken it to record intradayand closing highs without sustained declines. While thelong-term trend is still viewed as positive, many analysts saidthe momentum could wane in the absence of positive catalysts.

Retail sales rose 0.1 percent in April, better than the 0.3percent drop that had been expected, and returning to growthfollowing a decline in March.

Excluding autos, gasoline and building materials, core salesrose 0.5 percent. Retail sales account for about 30 percent ofU.S. consumer spending.

"Recent data has been weak, so to see some sturdiness isimportant and needed in order for us to move materially higher,"said Mark Luschini, chief investment strategist at JanneyMontgomery Scott in Philadelphia. "But given the strength we'vehad over the past few weeks, it isn't surprising that trading isa bit indifferent today."

The S&P 500 managed its third straight weekly gainlast week, reaching a record high on Friday. The benchmark had a five-day streak of record closing highs before settling loweron Thursday.

The Dow Jones industrial average was down 24.04points, or 0.16 percent, at 15,094.45. The Standard & Poor's 500Index was up 1.41 points, or 0.09 percent, at 1,635.11.The Nasdaq Composite Index was up 8.40 points, or 0.24percent, at 3,444.99.

Netflix Inc jumped 4.2 percent to $226.81 as one ofthe biggest advancing stocks in the S&P 500, helping to keep theNasdaq in slightly positive territory.

Other data showed business inventories were unchanged inMarch for a second straight month versus expectations of 0.3percent rise, suggesting restocking could help second-quartereconomic growth.

Crude oil fell 0.7 percent to $95.39 per barrel,pressured by a drop to an eight-month low in demand in China.

Luschini, who helps oversee $58 billion in assets, said thedrop in oil and gasoline prices contributed to the strong readon retail sales, "so it is helpful to see those remain tame.

"However, if we dip below $90 a barrel, that will hurt theenergy sector and could be a signal of lower global growth."

Consol Energy fell 2 percent to $34.14 whileNational Oilwell Varco was off 1.4 percent at $67.27.

Yum Brands Inc fell 2.6 percent to $68.54. After themarket closed on Friday, the fast food chain operator posted asteep decline in Chinese April sales.

With 90 percent of the S&P 500 having reported, 67.2 percentof companies have topped earnings expectations, according toThomson Reuters data, an amount that is even with the averageover the past four quarters. Only 46.9 percent have beatenrevenue expectations, under the 52 percent average over the pastfour quarters.

Elan agreed to a $1 billion deal to buy 21percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for itsrespiratory drugs. Theravance shares jumped 15 percent to$40.33.

U.S.-listed shares of Perion Network surged 12percent to $14.10 after the Israeli consumer Internet companyposted first-quarter earnings.

SoftBank Corp has told banks that their financingof Dish Network Corp's $25.5 billion rival offer forSprint Nextel Corp could hurt their chances of landing arole in a highly anticipated public offering of Chinesee-commerce giant Alibaba Group Holding Ltd, two sources familiarwith the situation said.

Sprint shares dipped 1.6 percent to $7.24 while Dish lost1.7 percent to $38.51.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.